Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 6Triple Negative Breast Neoplasms 1Lymphedema 1Breast Cancer Invasive 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

pembrolizumab 44Carboplatin 35Paclitaxel 27Specimen Handling 18Cyclophosphamide 16Capecitabine 16Magnetic Resonance Spectroscopy 14sacituzumab govitecan 13Gemcitabine 13Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9Doxorubicin 8olaparib 7Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Fulvestrant 4Epirubicin 4Bevacizumab 4veliparib 3famitinib 3abemaciclib 3Vinorelbine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Mastectomy × 90 days × Clear all
NCT02883062 2026-05-28

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
67 enrolled 16 charts
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡